AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28829526
Drug: Morphine-ADER-IMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-ADER-IMT
Trial: 9048348
Drug: Weekly subcutaneous
RxNorm normalized name: Weekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous (SC) rHuEPO at one third the weekly IV dose for 10 months
Trial: 9048348
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous (IV) rHuEPO therapy
Trial: 8315262
Drug: Ursodeoxycholic acid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid, 500 mg daily (about 8.7 mg/kg body weight)
Trial: 3443140
Drug: Metoprolol tartrate
RxNorm normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol tartrate 100 mg orally
Trial: 3443140
Drug: Metoprolol tartrate
RxNorm normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol tartrate 200 mg orally
Trial: 3443140
Drug: Metoprolol tartrate
RxNorm normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol tartrate 20 mg as a constant‐rate intravenous infusion over 20 min
Trial: 20724647
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g C10
Trial: 20724647
Drug: 23 g
RxNorm normalized name: PEG-23 GLYCERYL DISTEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23 g C10
Trial: 20724647
Drug: 23 g
RxNorm normalized name: PEG-23 GLYCERYL DISTEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23 g C10 (substituted for fats)
Trial: 20724647
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g (control)
Trial: 18272089
Drug: 24 mg
RxNorm normalized name: uracil 224 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg dexamethasone intravenously
Trial: 15709187
Drug: mTOR kinase
RxNorm normalized name: Kinase (enzyme-activating), uro-urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mTOR kinase inhibitor CCI‐779
Trial: 12566371
Drug: Lisinopril (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (30 mg/d, median, range: 10 to 40 mg/d)
Trial: 12566371
Drug: Lisinopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10 mg/d)
Trial: 12566371
Drug: Lisinopril (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (maximum doses)
Trial: 1896268
Drug: 0.1 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mL/kg of 1% lidocaine prior to the lumbar puncture
Trial: 6414822
Drug: Indomethacin 100
RxNorm normalized name: indomethacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 100 mg/day for 2.5 days
Trial: 6414822
Drug: Hydralazine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine 0.2 mg/kg intravenous injection after indomethacin
Trial: 6414822
Drug: Hydralazine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine 0.2 mg/kg intravenous injection after placebo
Trial: 28854208
Drug: Immediate group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate group (oral iron started concurrently with antimalarial treatment)
Trial: 28854208
Drug: Delayed group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed group (oral iron started 28 days after antimalarial treatment)
Trial: 25819861
Drug: Self-management intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management intervention conducted by a nurse focusing on medication goals, medication-symptom associations, and symptom response plan
Trial: 15301924
Drug: Progesterone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (200 mg, two oral doses)
Trial: 3325256
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment with ofloxacin during granulocytopenia after cytostatic treatment
Trial: 3325256
Drug: Control phases
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control phases (no ofloxacin prophylaxis) during cytostatic treatment
Trial: 3325256
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment with ofloxacin
Trial: 2435449
Drug: Imipramine or
RxNorm normalized name: imipramine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine or amitriptyline (150 mg)
Trial: 20108108
Drug: Chondroitin sulfate
RxNorm normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulfate and glucosamine (1,600 mg oral mixture, twice daily for 8 months)
Trial: 20108108
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for 8 months)
Trial: 17588298
Drug: Quarter-dose titration
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quarter-dose titration and acetaminophen
Trial: 17588298
Drug: Quarter-dose titration
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quarter-dose titration and ibuprofen
Trial: 17588298
Drug: Half-dose titration
RxNorm normalized name: Half Beta-Prograne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose titration and acetaminophen
Trial: 17588298
Drug: Half-dose titration
RxNorm normalized name: Half Beta-Prograne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose titration and ibuprofen
Trial: 17588298
Drug: Full-dose therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose therapy plus acetaminophen
Trial: 17588298
Drug: No titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No titration (control group)
Trial: 10441974
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate via nebulizers at a dosage of 2 mg twice daily for 4 weeks
Trial: 8527276
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cholestyramine ('Questran A')
Trial: 786680
Drug: Ibuprofen (Brufen:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (Brufen: 400 mg three times daily)
Trial: 28456141
Drug: Hormone use
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone use
Trial: 26074708
Drug: Levofloxacin-doxycycline-based triple
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin-doxycycline-based triple therapy with Lactobacillus casei DG (n = 71)
Trial: 26074708
Drug: Levofloxacin-doxycycline-based triple
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin-doxycycline-based triple therapy without Lactobacillus casei DG (n = 71)
Trial: 21234550
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch (PL)
Trial: 17095973
Drug: Inhaled nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitroglycerin (20 microg.kg(‐1))
Trial: 17095973
Drug: Inhaled iloprost
RxNorm normalized name: iloprost Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled iloprost (2.5 microg.kg(‐1))
Trial: 15155607
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol 200 micro g
Trial: 15155607
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol 400 micro g
Trial: 15155607
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol 800 micro g
Trial: 369076
Drug: Ciclobendazole (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclobendazole (600 mg to 1200 mg)
Trial: 15076014
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg adjunctive mirtazapine
Trial: 30835436
Drug: Bicarbonate (0.40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate (0.40 g/kg)
Trial: 28233458
Drug: β1-/β2-receptor-blockers (n=2219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β1-/β2-receptor-blockers (n=2219)
Trial: 28233458
Drug: High-dose β-blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose β-blockers (>25 mg carvedilol equivalent daily dose, n=1005)
Trial: 21270723
Drug: Sequential injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential injection of 1.5% mepivacaine followed 90 secs later by 0.5% ropivacaine
Trial: 21270723
Drug: Simultaneous injection
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous injection of 1.5% mepivacaine and 0.5% ropivacaine
Trial: 10689268
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium (30 mg/kg)
Trial: 20384753
Drug: Electrocoagulation (EC)
RxNorm normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrocoagulation (EC) treatment
Trial: 15716163
Drug: First-degree biological
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-degree biological relatives of schizophrenia patients
Trial: 11482924
Drug: Bisoprolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (5 mg x day(‐1))
Trial: 10426452
Drug: Single-agent docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-agent docetaxel (Taxotere) 100 mg/m2 every 3 weeks
Trial: 10426452
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy regimens (mitomycin C plus vinblastine, methotrexate plus 5‐fluorouracil, or 5‐fluorouracil plus vinorelbine)
Trial: 31538401
Drug: StandingTall exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: StandingTall exercise program delivered through tablet computers for 12 weeks
Trial: 28183567
Drug: Cormack-Lehane scores
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cormack-Lehane scores (C‐L)
Trial: 22188311
Drug: Daily topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily topiramate
Trial: 19958429
Drug: 5% niacinamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% niacinamide plus 1% N-undecylenoyl phenylalanine formulation
Trial: 19958429
Drug: 5% niacinamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% niacinamide formulation
Trial: 15320674
Drug: Dextrose treatment
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose treatment
Trial: 15320674
Drug: Honey treatment
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey treatment
Trial: 11282700
Drug: Dialectical behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical behavior therapy (DBT) for 20 weeks
Trial: 9274581
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (antianginal drugs)
Trial: 3103436
Drug: Etidronate, 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate, 7.5 mg/kg of body weight
Trial: 31281981
Drug: Continuous perineural
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous perineural local anesthetic infusion (CPI) with ropivacaine 0.2% administered at 2 mL/h for 72 hours
Trial: 31281981
Drug: Placebo (NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (NaCl 0.9%) administered at 2 mL/h for 72 hours
Trial: 27475032
Drug: Technology-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technology-based intervention promoting adherence to controller medication (two computer-delivered sessions based on motivational interviewing combined with text message reminders)
Trial: 21780974
Drug: 250 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ppm AmF/SnF(2) solution (Meridol) - extra-oral application
Trial: 21780974
Drug: CPP-ACP crème
RxNorm normalized name: tocopherol acetate / vitamin A palmitate Topical Cream [Lazer Creme]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPP-ACP crème (Tooth Mousse) - extra-oral application
Trial: 21780974
Drug: 250 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ppm AmF/SnF(2) solution (Meridol) - intra-oral application
Trial: 21780974
Drug: CPP-ACP crème
RxNorm normalized name: tocopherol acetate / vitamin A palmitate Topical Cream [Lazer Creme]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPP-ACP crème (Tooth Mousse) - intra-oral application
Trial: 17433732
Drug: Iloprost (intra-arterial,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloprost (intra-arterial, intra-operative bolus of 3000 ng, plus intravenous infusion of 0.5-2.0 ng/kg/min for six hours/day for 4-7 days following surgery)
Trial: 10403597
Drug: VAQTA 25
RxNorm normalized name: Vaqta 25 UNT per 0.5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAQTA 25 U (3 doses)
Trial: 10403597
Drug: HAVRIX 720
RxNorm normalized name: Havrix 720 UNT per 0.5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAVRIX 720 EU (3 doses)
Trial: 7651666
Drug: Tocolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocolytic therapy (MgSO4 and terbutaline as first-line agents)
Trial: 2275566
Drug: Netilmicin, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netilmicin, 3 doses
Trial: 7371700
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal 50 g ingested within 5 min of taking the drugs
Trial: 7371700
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal 118 g in 5 divided doses given between 10 and 48 hr after ingestion of phenobarbitone
Trial: 19056618
Drug: Lanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanthanum carbonate (3000 mg/d)
Trial: 17697359
Drug: Dextran-70 infusion
RxNorm normalized name: Dextran 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran-70 infusion at a dose of 7.5 ml/kg before cardiopulmonary bypass and 12.5 ml/kg after cessation of cardiopulmonary bypass
Trial: 17697359
Drug: Dextran-70 infusion
RxNorm normalized name: Dextran 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran-70 infusion
Trial: 17697359
Drug: Gelatin infusion
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin infusion (Control)
Trial: 9745419
Drug: Testosterone patches
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone patches (5 mg testosterone over 24 h)
Trial: 29433578
Drug: Sequential nephron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential nephron blockade (thiazide diuretic, aldosterone-receptor blocker, furosemide, amiloride)
Trial: 29433578
Drug: Dual blockade
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual blockade of the RAAS (ACE inhibitor plus beta-blocker)
Trial: 26463170
Drug: Culturally consistent
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally consistent diabetes educational program led by a Latino pastor, including weekly reviews of the American Diabetes Association's booklets on diabetes education.
Trial: 25062874
Drug: Nafamostat (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafamostat (20 mg)
Trial: 22399616
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² i.v. d1 q3 weeks (tT)
Trial: 22399616
Drug: Docetaxel 50
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 50 mg/m² i.v. d1 and d 14, q4 weeks (bT)
Trial: 20616541
Drug: Non-SCT (further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-SCT (further intensive post-remission non-myeloablative chemotherapy or no further therapy)
Trial: 15129752
Drug: Concurrent nontemporal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent nontemporal task
Trial: 15129752
Drug: No concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No concurrent task
Trial: 8831331
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg/kg + 5 mg.kg‐1.h‐1)
Trial: 1485475
Drug: Intravenous Actovegin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Actovegin 20% (250 ml daily infusion)
Trial: 3934453
Drug: L-triiodothyronine (LT3)
RxNorm normalized name: L-3,5,3'-Triiodothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-triiodothyronine (LT3) administration
Trial: 3934453
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no LT3 administration)
Trial: 3934453
Drug: Sodium ipodate
RxNorm normalized name: ipodate sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ipodate administration
Trial: 30245330
Drug: Cortisol administration
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol administration (20 mg hydrocortisone)
Trial: 28854590
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg, increased to 5 mg if non-responders)
Trial: 28854590
Drug: Clomiphene Citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene Citrate (CC) (50 mg, increased to 100 mg if non-responders)
Trial: 17854590
Drug: linaclotide 1000
RxNorm normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: linaclotide 1000 microg once daily
Trial: 17854590
Drug: linaclotide 100
RxNorm normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: linaclotide 100 microg once daily
Trial: 11333130
Drug: DBDT regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBDT regimen (BCNU 150 mg/m2 i.v. on day 1, cisplatin 25 mg/m2 i.v. daily on days 1 to 3, DTIC 220 mg/m2 i.v. daily on days 1 to 3, tamoxifen 160 mg orally daily for 7 days prior to chemotherapy)
Trial: 11333130
Drug: DTIC alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC alone (1200 mg/m2 i.v. on day 1, repeated every 21 days)
Trial: 8239808
Drug: Antiplatelet drug
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet drug regimens
Trial: 3120345
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate 20 mg four times daily
Trial: 30217958
Drug: Inhaled nemiralisib
RxNorm normalized name: Nemiralisib
DrugBank: Nemiralisib (DB16253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nemiralisib (1000 µg)
Trial: 27012781
Drug: Whole prasugrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole prasugrel 60-mg loading dose
Trial: 24975869
Drug: Anticoagulant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant treatment eligibility
Trial: 22619259
Drug: IV elinogrel
RxNorm normalized name: Elinogrel
DrugBank: Elinogrel (DB06350)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV elinogrel (120 mg) plus oral elinogrel (100 mg twice daily)
Trial: 22619259
Drug: IV elinogrel
RxNorm normalized name: Elinogrel
DrugBank: Elinogrel (DB06350)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV elinogrel (120 mg) plus oral elinogrel (150 mg twice daily)
Trial: 22619259
Drug: IV and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV and oral elinogrel
Trial: 18584919
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity warfarin anticoagulation
Trial: 18584919
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist anticoagulants
Trial: 16159905
Drug: Early childhood
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early childhood stimulation intervention with weekly home visits by community health aides for one year.
Trial: 9864073
Drug: pill placebo-case
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pill placebo-case management (Pbo-CM)
Trial: 9864073
Drug: cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cognitive behavior therapy (CBT)